WaveFront Dynamics Announces First Close of a $3 Million Series A Financing Round

WaveFront Dynamics today announced the first close of a $3 million Series A financing round. The round was led by new investor Tramway Venture Partners LP and included investments from a Phoenix Venture Partners LP affiliate and an additional angel investor. In connection with the financing, Waneta Tuttle of Tramway Venture Partners and Frank Levinson of Phoenix Venture Partners will join WaveDyn’s Board of Directors. The funds will support the continued development of its ophthalmic measurement device with dynamic wavefront technology and subsequent clinical studies. 

WaveFront Dynamics founder and CEO of WaveDyn, Dan Neal, PhD, is an optical scientist with the vision to develop novel methods to assess the visual performance of the human eye. The eye is continuously changing as it focuses on objects at various distances. WaveDyn is developing proprietary methods to measure changes of the eye dynamically, over a sequence in time, rather than a single snapshot. The company will leverage its dynamic wavefront measurement capabilities to create ophthalmic treatment solutions for patients with complex visual dysfunction.

“The dynamic wavefront-guided treatment has the potential for improving the vision of hundreds of thousands of patients in the US alone,” said Neal. “We’re happy to partner with lead investor Tramway Venture Partners, along with Phoenix Venture Partners’ affiliate, who have well-earned reputations working with early-stage startups. We look forward to working with this team of investors, who bring years of business and technical experience in support of our new venture.”

“We are excited to add WaveDyn to the Tramway portfolio,” said Waneta Tuttle, Fund Manager for Tramway. “We were first attracted to the company by the experience of this talented team. We became increasingly interested in investing as we learned about the business plan and its approach to both diagnosing and correcting serious vision problems.”

“Dan and his team have already proven their ability to deliver ground-breaking ophthalmic instruments,” said Frank Levinson, General Partner for Phoenix Venture Partners and its affiliate. “We’re excited to work along with the WaveDyn team. Their technology has the potential to bring unprecedented comfort and visual acuity for patients and lends itself to an attractive business model facilitated by a concentrated market access.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”